← Back to Search

Behavioral Intervention

Smartphone App for Opioid Use Disorder

N/A
Recruiting
Research Sponsored by Western Michigan University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged 18 or older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 17-48

Summary

This trial aims to see if a smartphone app can help people with opioid use disorder. Participants will use the app to submit videos of themselves taking drug tests. The app also provides reminders, rewards, and

Who is the study for?
This trial is for adults over 18 in the U.S. who have opioid use disorder, can read and speak English, own a compatible smartphone, and have used opioids recently. They should be starting or already receiving medication-assisted treatment and have an ASAM CO-Triage score from L1 to L3.1.
What is being tested?
The study tests if a smartphone app providing reminders, rewards, cognitive-behavior therapy modules, wellness activities, and live support helps people with opioid addiction. Participants submit weekly drug test videos for one year.
What are the potential side effects?
Since this trial involves non-medical interventions like app-based services and support rather than drugs or medical procedures, traditional side effects are not applicable.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 17-48
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 17-48 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Independent lab-based salivary drug toxicology for abstinence from all unprescribed drugs (initial 16 weeks)
Secondary study objectives
Days of Medications for Opioid Use Disorder (MOUD) adherence
Frequency of Adverse Events
Healthcare utilization
+2 more
Other study objectives
Quality of Life assessment
Self-conducted abstinence from all unprescribed drugs
Self-reported drug use
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Abstinence reinforcementExperimental Treatment3 Interventions
Participants earn incentives for submission of salivary drug toxicology video selfies that show test results consistent with the goals of treatment. Goals are abstinence-based (i.e., relate to which tested substances should be negative on the test given the medications that the particular participant has been prescribed). Incentives are also provided for attendance at treatment-related appointments and for completion of self-paced cognitive behavior therapy modules available via the smartphone app.
Group II: Sample-contingent controlPlacebo Group3 Interventions
Identical to the experimental group except that incentives are available only for submission of selfie-videos that show test results, without regard to the results of the salivary drug toxicology test. Similarly, incentives are not provided for appointments or completion of wellness modules.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Contingency management
2006
Completed Phase 4
~1020

Find a Location

Who is running the clinical trial?

Western Michigan UniversityLead Sponsor
16 Previous Clinical Trials
2,628 Total Patients Enrolled
RTI InternationalOTHER
196 Previous Clinical Trials
844,296 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,582 Previous Clinical Trials
3,326,790 Total Patients Enrolled
~141 spots leftby Aug 2025